By
Helen Cox et al.
Published: Sept. 6, 2017, 11:52 p.m.·
Tags:
Drug-resistant TB,
Treatment
A correspondence published in The Lancet addresses the issue of prevention of hearing loss in patients with multidrug-resistant TB by using newer drugs bedaquiline or delamanid, and repurposed drugs linezolid and clofazimine, instead of an injectable agent.
Read More →